Epitome Therapeutics Raises €4M for Gene Expression Editing

Vienna-based biotech innovator, Epitome Therapeutics, has officially launched with a substantial €4 million in initial funding, signaling strong investor confidence in its novel approach to epigenome editing. The company is pioneering a technology designed for precise, tunable control over gene expression, a critical area for treating a wide range of diseases that current gene silencing methods cannot address.

The financing comprises a €2 million pre-seed round, which was reportedly oversubscribed, and an additional €2 million from competitive grant programs. Leading the pre-seed investment were venture capital firms XISTA Science Ventures and Caesar Ventures, with participation from Navec Venture Holding GmbH. Further crucial support was secured through grants from prominent Austrian funding bodies, including the Austria Wirtschaftsservice (aws) and the österreichischen Forschungsförderungsgesellschaft (FFG), underscoring the project's scientific merit and potential impact.

Founded in 2025 by researchers Guido Gualdoni and Jamie Hackett, Epitome Therapeutics emerged from the prestigious EMBL in Rome. Their proprietary platform, dubbed 'CADENCE', aims to achieve sustained and finely adjusted activation of gene expression without altering the underlying DNA sequence. This modular system leverages a library of optimized epigenetic effectors, allowing for adaptation to diverse biological contexts and offering a significant advancement over existing technologies that often struggle with nuanced gene regulation.

The substantial capital infusion will be instrumental in advancing Epitome Therapeutics' development programs toward the nomination of its first drug candidate. The company also plans to broaden the capabilities of its CADENCE platform and expand its scientific and operational teams. "We established Epitome Therapeutics with the backing of a formidable group of investors and partners," stated Guido Gualdoni, Co-founder and CEO. The company's focus on restoring or enhancing gene activity, rather than solely silencing it, addresses a significant unmet need in therapeutic development, particularly for conditions stemming from insufficient or imbalanced gene expression.

The market for gene therapy and precision medicine is experiencing rapid growth, with significant investment flowing into companies developing innovative genetic modulation techniques. Epitome Therapeutics' focus on precise gene activation positions it within a dynamic segment of the biotech industry. The CADENCE platform's emphasis on precision, flexibility, and safety aims to overcome limitations of current gene activation strategies. This approach is particularly relevant for rare genetic disorders and metabolic diseases where precise control of gene output is paramount for therapeutic success.

Jamie Hackett, Co-founder and CSO, highlighted the platform's potential: "Many diseases arise when the delicate balance of gene expression is disrupted. The CADENCE platform enables precise control, allowing us to restore specific gene activity to therapeutically relevant levels. We believe this precision medicine approach represents a fundamentally new therapeutic modality for genetic and complex diseases." This sentiment was echoed by Alexander Schwartz, Partner at XISTA Science Ventures, who noted the team's impressive ability to translate scientific insights into actionable development programs.